178 related articles for article (PubMed ID: 9000839)
1. A comparative study of: long-term alpha-1-blocker, Doxazosin therapy versus surgery in the treatment of benign prostatic hyperplasia.
Dutkiewicz S
Mater Med Pol; 1995; 27(4):151-2. PubMed ID: 9000839
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
[TBL] [Abstract][Full Text] [Related]
3. Serum PSA levels at 6 month after surgery, TURP or Doxazosin therapy for BPH.
Dutkiewicz S; Stepień K
Mater Med Pol; 1996; 28(2):69-70. PubMed ID: 9088130
[TBL] [Abstract][Full Text] [Related]
4. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
Gratzke P; Kirby RS
Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
[TBL] [Abstract][Full Text] [Related]
5. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
McConnell JD; Roehrborn CG; Bautista OM; Andriole GL; Dixon CM; Kusek JW; Lepor H; McVary KT; Nyberg LM; Clarke HS; Crawford ED; Diokno A; Foley JP; Foster HE; Jacobs SC; Kaplan SA; Kreder KJ; Lieber MM; Lucia MS; Miller GJ; Menon M; Milam DF; Ramsdell JW; Schenkman NS; Slawin KM; Smith JA;
N Engl J Med; 2003 Dec; 349(25):2387-98. PubMed ID: 14681504
[TBL] [Abstract][Full Text] [Related]
6. Doxazosin-alpha-1-adrenergic antagonists drug in the long-term (3 years). Management of benign prostatic hyperplasia.
Dutkiewicz S
Mater Med Pol; 1996; 28(3):93-102. PubMed ID: 9167419
[TBL] [Abstract][Full Text] [Related]
7. [Experience in the use of doxazosin in patients with benign hyperplasia of the prostate].
Lopatkin NA; Loran OB; Pushkar' DIu; Perepanova TS; Tevlin KP
Urol Nefrol (Mosk); 1998; (3):3-5. PubMed ID: 9644978
[TBL] [Abstract][Full Text] [Related]
8. Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients.
Xue Z; Zhang Y; Ding Q; He Z; Wang J; Xu K
Int J Urol; 2007 Feb; 14(2):118-22. PubMed ID: 17302567
[TBL] [Abstract][Full Text] [Related]
9. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
McDonald H; Hux M; Brisson M; Bernard L; Nickel JC
Can J Urol; 2004 Aug; 11(4):2327-40. PubMed ID: 15380054
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
[TBL] [Abstract][Full Text] [Related]
11. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
12. Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice.
Chung BH; Hong SJ; Lee MS
Int J Urol; 2005 Feb; 12(2):159-65. PubMed ID: 15733110
[TBL] [Abstract][Full Text] [Related]
13. Effect of doxazosin on the symptoms of benign prostatic hyperplasia: results from three double-blind placebo-controlled studies.
Mobley DF; Kaplan S; Ice K; Gaffney M; Dias N
Int J Clin Pract; 1997; 51(5):282-8. PubMed ID: 9489085
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Roehrborn CG; Siegel RL
Urology; 1996 Sep; 48(3):406-15. PubMed ID: 8804494
[TBL] [Abstract][Full Text] [Related]
15. [Clinical effectiveness and safety of combined therapy with an alpha-blocker and an anticholinergic drug for patients with benign prostatic hyperplasia].
Xiao H; Li HZ; Huang ZM; Li YQ
Zhonghua Wai Ke Za Zhi; 2010 Dec; 48(23):1771-3. PubMed ID: 21211380
[TBL] [Abstract][Full Text] [Related]
16. Apoptotic regression of prostatic tissue induced by short-term doxazosin treatment in benign prostatic hyperplasia.
Türkeri LN; Ozyürek M; Ersev D; Akdaş A
Arch Esp Urol; 2001 Mar; 54(2):191-6. PubMed ID: 11341128
[TBL] [Abstract][Full Text] [Related]
17. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia.
Fitzpatrick JM; Desgrandchamps F
BJU Int; 2005 Mar; 95(4):575-9. PubMed ID: 15705083
[TBL] [Abstract][Full Text] [Related]
18. [Doxazosin treatment of disorders of the voiding phase in benign prostatic hyperplasia].
Esteban Fuertes M; Salinas Casado J; Virseda Chamorro M; Ramírez Fernández JC; Salomon Moh'd S; Luengo Alpuente S; Resel Estévez L
Arch Esp Urol; 1997 Dec; 50(10):1057-66. PubMed ID: 9494194
[TBL] [Abstract][Full Text] [Related]
19. The early effects of doxazosin on benign prostatic hyperplasia.
Akan H; Başar M; Dalva I; Başar H
Arch Ital Urol Androl; 1998 Feb; 70(1):41-4. PubMed ID: 9549168
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
Chung BH; Hong SJ
BJU Int; 2006 Jan; 97(1):90-5. PubMed ID: 16336335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]